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Abstract
Multiple combinational regimens have recently been approved and are now considered the standard of care for patients with advanced clear cell 
renal cell carcinoma (RCC). Several additional combinational regimens are deep in clinical assessment and are likely to soon join the crowded 
front-line therapeutic landscape. Most of these regimens are combinations of agents already approved as single-agents in RCC including tyrosine 
kinase inhibitors (TKI) and immune checkpoint inhibitors. While these new front-line regimens are associated with reliably high response rates 
and prolonged survival, complete and durable remissions remain limited to a small subset of patients and the vast majority of patients continue 
to require subsequent therapy. The need for the continued development of novel agents in RCC persists and efforts have focused on agents 
targeting the molecular biology of clear cell RCC and novel immunotherapies including cytokines. In this review, we discuss the progress in the 
development of these novel therapies in the context of the evolving standard of care for patients with advanced clear cell RCC.
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Renal cell carcinoma (RCC) is the seventh most common 
malignancy in the USA with over 73,000 cases and 14,830 
deaths expected in 2020 (1). The majority of patients pres-
ent with localized disease, however, approximately one-third 
present with locally advanced or metastatic disease and up to 
30% of patients undergoing surgical resection will experience 
recurrent disease (2). Before 2006, the only available treat-
ments for advanced clear cell RCC were interferon (IFN)-α 
and interleukin-2 (IL-2), both cytokine therapies associated 
with serious toxicity and limited efficacy (3). Between 2006 
and 2010, the approval of multiple tyrosine kinase inhibi-
tors (TKI) contributed to a doubling in the median survival 
time from around 15 to 30 months (4). The following sev-
eral years has seen the rapid development and approval of 
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including PBRM1, BAP1, and SETD2 (present in 38.0, 11.0, 
and 13.2%, respectively) (8). While these mutations appear 
to have prognostic value (PBRM1 loss appears to be associ-
ated with favorable outcomes while BAP1 loss is associated 
with unfavorable outcomes), the predictive value with respect 
to specific therapies continues to be explored (16, 17). For 
example, a recent study has shown that PBRM1 loss may be 
associated with reduced clinical benefit in response to immu-
notherapy due to a decrease in STAT1 phosphorylation and 
subsequent enhancement of IFNγ gene expression (18). 
Recent Developments in Systemic Therapy  
for Clear Cell RCC
Most patients with newly diagnosed advanced clear cell RCC 
will immediately begin systemic therapy. However, an area 
of controversy in the field remains, the role of cytoreduc-
tive nephrectomy for the subset of patients presenting with 
metastatic RCC and primary tumor in place. Historically, 
the standard of care for clinically appropriate patients was 
to undergo a debulking nephrectomy based on the results 
from a randomized Phase II trial in which patients random-
ized to receive a nephrectomy followed by IFNα had supe-
rior survival compared with those randomized to IFNα 
alone (19). Recent studies in the TKI era have challenged this 
practice. The SURTIME trial found that patients random-
ized to receive sunitinib followed by delayed cytoreductive 
nephrectomy had improved overall survival (OS) compared 
with those randomized to undergo immediate cytoreductive 
nephrectomy followed by sunitinib, although there was no 
significant difference in progression-free survival (PFS) (20). 
As OS was a secondary endpoint, the study was felt to be 
underpowered to draw a definitive conclusion based on this 
endpoint. The CARMENA study randomized 450 patients 
to either sunitinib alone or cytoreductive nephrectomy fol-
lowed by sunitinib and found that sunitinib alone was not 
inferior to cytoreductive nephrectomy followed by sunitinib 
with respect to OS (21). Following this, a subsequent anal-
ysis suggested that there may be a benefit for cytoreductive 
nephrectomy for patients with only one risk factor by Interna-
tional Metastatic Renal Cell Database Criteria (IMDC) (22). 
Thus, currently, the decision on whether or not to undergo 
a debulking nephrectomy remains a clinical decision and 
the value of this approach with frontline immunotherapy 
remains unclear. The Southwest Oncology Group (SWOG) 
has initiated a study randomizing patients who are neither 
immediate progressors nor complete responders following 
induction immunotherapy to either cytoreductive nephrec-
tomy followed by systemic therapy or systemic therapy alone. 
This study will hopefully add more clarity on the value of 
cytoreductive nephrectomy in the context of immunotherapy. 
Once patients start systemic treatment, the standard 
treatment for clear cell RCC for many years consisted of 
next-generation TKIs (cabozantinib and lenvatinib) as well 
as the approval of immune checkpoint inhibitors (nivolumab, 
ipilimumab, and pembrolizumab) either as single agents or 
in combinational regimens. In light of the numerous recent 
changes to the RCC therapeutic landscape, we will briefly 
review the molecular biology of clear cell RCC and the cur-
rent standard of care for advanced clear cell RCC and then 
discuss emerging therapies in this rapidly evolving context. 
The primary objective of this review is to provide insight 
into how the novel therapies currently under investigation in 
clear cell RCC have evolved from our understanding of the 
biology of this disease as well as the clinical experience with 
standard agents thus far. 
Molecular Biology of Clear Cell RCC
While RCC is a heterogeneous disease, the clear cell his-
tologic subtype remains the most common representing 
approximately 70% of all renal tumors and an even larger 
proportion of patients with metastatic RCC (>80%) (4–6). 
The vast majority of clear cell RCC is characterized by bial-
lelic loss of function of the von Hippel Lindau (VHL) tumor 
suppressor gene. Loss of the short arm of chromosome 3, 
which contains the VHL gene, has been found in 70–90% 
of clear cell RCC and is believed to be the earliest event in 
tumorigenesis (7, 8). The loss of function of the remaining 
copy of VHL subsequently occurs by somatic mutation, 
deletion, or epigenetic silencing. VHL forms a part of the 
oxygen-dependent VHL E3 ubiquitin ligase complex which 
functions to promote the ubiquitinylation and subsequent 
proteasomal degradation of hydroxylated proteins (9). The 
Cancer Genome Analysis (TCGA) for RCC also character-
ized low-frequency mutations in other members of the VHL 
complex (e.g., TCEB1, CUL2) in clear cell RCC not possess-
ing alterations in VHL, suggesting that loss of function of 
the VHL complex is a central feature of nearly all clear cell 
RCC (10). Two of the best-studied target proteins for the 
VHL complex are the transcription factors—hypoxia-induc-
ible factors, (HIF)-1α and -2α (11). Loss of VHL function 
results in accumulation of both HIF-1α and HIF-2α and 
the subsequent activation of their target genes, including 
vascular endothelial growth factor (VEGF), platelet-derived 
growth factor (PDGF), transforming growth factor-alpha 
(TGF-α), erythropoietin, GLUT-1, and CXCR4 (12–14). 
In addition to the loss of chromosome 3p and subsequent 
loss of VHL, another critical event in clear cell RCC tumor-
igenesis is the gain of chromosome 5q, which occurs in 67% 
of RCC, and loss of chromosome 14q, occurring in 45% (8). 
Studies have also shown that loss of 3p and gain of 5q can 
occur simultaneously through chromothripsis in up to 28% 
of RCC and this may be the initial tumorigenic event in these 
tumors (15). Clear cell RCC is also characterized by lower 
frequency somatic mutations in chromatin remodeling genes, 
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847 patients with intermediate or poor-risk features by IMDC 
risk category. Patients who had received the combination of 
ipilimumab and nivolumab experienced superior objective 
response rate (ORR) (42 vs 27%; P < 0.001) and 18-month 
overall survival (OS) rate (75 vs 60%; 95% CI 55 to 65) com-
pared with those treated with sunitinib. At the time of the 
most recent update after 42 months of follow-up, patients 
with intermediate or poor-risk RCC treated with ipilimumab 
and nivolumab had experienced a superior median OS (47.0 
vs 26.6 months; HR 0.66; 95% CI 0.55 to 0.80; P < 0.0001), 
PFS (11.6 vs 8.3 months; HR 0.75; 95% CI 0.62 to 0.90; P < 
0.0015), and maintained superior ORR (42.1 vs 26.3%; P < 
0.001) (24). In patients with favorable risk, similar advan-
tages to ipilimumab and nivolumab were not observed with 
patients treated with the combination experiencing ORR of 
sequential, mostly single-agent therapy with either immuno-
therapy, VEGF-targeted agents, or inhibitors of mammalian 
target of rapamycin (mTOR). These agents are outlined in 
Table 1. In the last 3 years, three combinational regimens 
have been approved for first-line therapy which have reshaped 
the therapeutic landscape.
Ipilimumab plus nivolumab
The combination of nivolumab (a monoclonal antibody 
(Ab) targeting programmed death (PD)-1) and ipilimumab 
(a monoclonal Ab targeting cytotoxic T-lymphocyte-associ-
ated protein (CTLA-4)) was assessed in a randomized Phase 
III trial versus sunitinib in patients with untreated advanced 
RCC (23). The initial publication reported the results of 
Table 1: Approved drugs and regimens for patients with advanced RCC.
Drug/Regimen Mechanism of action FDA approval date NCCN category
Sorafenib TKI targeting VEGFR, 
PDGFR, KIT, RAF
12/20/2005 2B: subsequent line, all risk groups
Sunitinib TKI targeting VEGFR, 
PDGFR, KIT, RET
01/26/2006 2A: first and subsequent line, all risk 
groups
Temsirolimus mTOR inhibitor 05/30/2007 2A: first line in poor/intermediate risk 
groups; 2B: subsequent line all risk groups 
Everolimus mTOR inhibitor 03/30/2009 2A: subsequent line all risk groups
Bevacizumab + IFNα Monoclonal Ab against 
VEGF
07/31/2009 2B: subsequent line all risk groups
Pazopanib TKI targeting VEGF, 
PDGFR, KIT
10/19/2009 2A: first and subsequent line, all risk 
groups
Axitinib TKI targeting VEGFR 1-3, 
KIT, PDGFR
01/27/2012 1: subsequent line all risk groups; 2B: 
subsequent line poor/intermediate-risk 
groups
Nivolumab Monoclonal Ab against PD-1 11/23/2015 1: subsequent line all risk groups
Cabozantinib TKI targeting VEGFR2, 
MET, AXL, RET
04/24/2016 1: subsequent line all risk groups; 2A: 
first-line poor/intermediate-risk groups; 
2B: first-line good risk
Lenvatinib +/-  
Everolimus
TKI targeting VEGFR 1-3, 
FGFR, PDGFR, KIT, RET
05/13/2016 1: subsequent line all risk groups
Ipilimumab + 
Nivolumab
Monoclonal Ab against 
CTLA4 and PD-1
04/16/2018 1: first-line poor/intermediate-risk; 2A: 
first and subsequent line all risk groups
Axitinib + 
Pembrolizumab
TKI plus PD-1 Ab 04/19/2019 1: first-line poor/intermediate-risk; 2A: 
first and subsequent line all risk groups
Axitinib + Avelumab TKI plus PD-L1 Ab 05/14/2019 2A: first-line all risk groups; 3: subsequent 
line all risk groups
Toth AT and Cho DC
 Journal of Kidney Cancer and VHL 2020; 7(4): 17–26 20
28.8 versus 54.0% (P < 0.0001) and HR for death of 1.19 
(95% CI 0.77 to 1.85) compared with patients treated with 
sunitinib. Across all risk categories, patients treated with 
ipilimumab and nivolumab had a greater median duration 
of response (NR vs 24.8 months; HR 0.48; 95% CI 0.34 to 
0.67; P < 0.0001) and more complete responses (10.1–12.8% 
vs 1.4–5.6%, intermediate/poor risk–favorable risk) com-
pared with sunitinib. Based on the initial results, the United 
States Food and Drug Administration (FDA) approved the 
combination of ipilimumab and nivolumab as first-line treat-
ment for patients with intermediate/poor-risk advanced RCC 
in April 2018 and this treatment now carries a category 1 
recommendation for intermediate/poor-risk RCC and cate-
gory 2A recommendation for favorable risk RCC as per the 
guidelines of the National Comprehensive Cancer Network 
(NCCN) (19, 25).
Axitinib plus pembrolizumab
The combination of axitinib and pembrolizumab (a mono-
clonal Ab targeting PD-1) was assessed in a randomized 
Phase III trial versus sunitinib in patients with advanced 
RCC (KEYNOTE-426) (26). Overall, 861 patients were 
randomized to receive either the combination of axitinib 
and pembrolizumab or sunitinib. Patients who received the 
combination of axitinib and pembrolizumab experienced sig-
nificantly better median PFS (15.1 vs 11.1 months; HR 0.69; 
95% CI 0.38 to 0.74; P < 0.001), ORR (59.3 vs 35.7%; P < 
0.001), and 12-month survival rate (89.9 vs 78.3%, HR 0.53; 
95% CI 0.38 to 0.74; P < 0.0001). The benefit of axitinib 
and pembrolizumab over sunitinib was observed across all 
IMDC risk groups and was irrespective of PD-L1 expres-
sion. Based on these results, the combination of axitinib and 
pembrolizumab was approved by the FDA in April 2019 for 
patients with advanced RCC regardless of IMDC risk group 
and currently is given a category 1 recommendation by the 
NCCN for first-line therapy.
Axitinib plus avelumab
The combination of axitinib and avelumab (monoclonal 
Ab targeting PD-L1) was similarly assessed in a large ran-
domized Phase III trial versus sunitinib in patients with 
advanced RCC in which 886 treatment-naïve patients were 
randomized to receive either the combination or sunitinib 
(JAVELIN). The study was designed with the primary end-
points of PFS and OS among patients with PD-1 Ligand 
(PD-L1) positive tumors. In the initial report of the results, 
the combination of axitinib and avelumab resulted in supe-
rior PFS in both patients with PD-L1 positive tumors (13.8 
vs 7.2 months; HR 0.61, 95% CI 0.47 to 0.79; P < 0.001) and 
the overall population (13.8 vs 9.4 months; HR 0.69; 95% 
CI 0.56 to 0.84; P  <  0.001) compared with sunitinib (27). 
The combination also resulted in superior ORR in both the 
PD-L1 positive population (55.2 vs 25.5%) and in the over-
all study population (51.4 vs 25.7%). The clinical benefits 
were observed across all IMDC risk groups. At the time of 
the most updated results, OS data were still not mature (28). 
Based on these results, the combination of axitinib and ave-
lumab was approved by the FDA in May 2019 for patients 
with advanced RCC regardless of IMDC risk group and is 
also currently given a category 1 recommendation by the 
NCCN for first-line therapy. 
Subsequent Therapy
The most current standard care for the majority of patients 
with advanced clear cell RCC will be to start treatment 
with combinations of ipilimumab–nivolumab, axitinib– 
pembrolizumab, or axitinib–avelumab. However, as noted 
above, complete responses that are maintained off therapy are 
rare and the vast majority of patients will require subsequent 
lines of therapy. With the changes to frontline therapy being 
so recent, the most appropriate choice of second-line therapy 
remains unclear. A small retrospective analysis has shown 
that the combination of ipilimumab–nivolumab has moder-
ate activity in patients treated with prior therapy including the 
combination of TKI–checkpoint inhibitors (29). As patients 
treated initially with ipilimumab–nivolumab are TKI-naïve, 
logical second-line options would include single-agent TKI 
and TKI–checkpoint inhibitor combinations. This remains 
an area that needs novel therapeutic development and we will 
review some progress in this regard in the following sections. 
Determination of the most appropriate sequence of the 
agents will require continued efforts to develop predictive 
biomarkers of response to current therapies. While signif-
icant effort has gone into identifying mechanisms of resis-
tance to VEGF-targeted therapies, whether these same 
pathways will be relevant when VEGF-targeted therapies are 
combined with immune therapy remains unclear (30). Simi-
larly, no clear predictors of resistance to the combination of 
ipilimumab and nivolumab have been identified. 
First-line Trials in Progress with TKI plus 
Immunotherapy
Several important clinical trials are underway which may 
also contribute to the first-line RCC treatment paradigm 
(Table 2). Many of these trials are assessing combinations 
of second-generation TKI with PD-1 antibodies to build 
on the positive results from the KEYNOTE-426 and JAV-
ELIN studies. Positive results were recently announced for 
the CheckMate-9ER which is a randomized Phase III trial 
of cabozantinib plus nivolumab versus sunitinib in patients 
with previously untreated advanced clear cell RCC (31). In a 
press release, it was announced that patients treated with the 
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Table 2: Important ongoing clinical trials in patients with advanced RCC.
Title Drugs/Design Line of therapy
Checkmate-9ER Randomized Phase III trial of cabozatinib plus nivolumab versus sunitinib First
CLEAR Randomized Phase III trial of lenvatinib with everolimus or pembrolizumab 
versus sunitinib 
First
COSMIC-313 Randomized Phase III trial of cabozantinib plus ipilimumab and nivolumab 
versus ipilimumab and nivolumab
First
MK-6482-005 Randomized Phase III trial of MK6482 versus everolimus Second–Fourth
CANTATA Randomized double-blind Phase II trial of CB-839 plus cabozatinib versus 
cabozanitinib
Second–Third
PIVOT-09 Randomized Phase III trial of bempegaldesleukin plus nivolumab versus 
sunitinib or cabozantinib
First
combination of cabozantinib and nivolumab experienced a 
superior PFS, OS, and ORR compared with patients treated 
with sunitinib. The CLEAR trial is a randomized Phase III 
of the combination of lenvatinib with everolimus or pembroli-
zumab versus sunitinib in previously untreated patients with 
advanced clear cell RCC that has completed accrual. Finally, 
the COSMIC-313 trial is a randomized Phase III trial of 
cabozantinib in combination with iplimumab and nivolumab 
versus ipilimumab and nivolumab in previously untreated 
patients with advanced clear cell RCC with poor or intermedi-
ate risk factors. Positive results from any of these studies would 
be expected to result in approvals of new combinational regi-
mens in the first-line setting. In the current paradigm, practi-
tioners are choosing between a pure immunotherapy regimen 
(ipilimumab/nivolumab) versus the combination of a TKI and 
PD-1/PD-L1 Ab. However, compelling results from the com-
bination of cabozantinib with ipilimumab and nivolumab in 
the COSMIC 313 trial might establish this combination as the 
dominant option in first-line treatment. 
Novel Agents in Development in RCC
While the studies discussed thus far involve combinational 
regimens involving agents that are already approved in RCC, 
there are also numerous agents in clinical development in 
clear cell RCC with completely novel mechanisms of action. 
Like the VEGF-targeted therapies, many of these novel 
agents target therapeutic vulnerabilities engendered by the 
molecular biology of clear cell RCC. 
HIF2 inhibitors
The novel agents perhaps most centrally targeted to the 
molecular biology of clear cell RCC are inhibitors of 
HIF-2α. Numerous studies have established that HIF-2 is 
the more relevant HIF isoform in terms of RCC tumorigen-
esis and progression (32–35). While numerous strategies have 
been developed to target the HIFs, one which has emerged 
are allosteric inhibitors which bind to the PAS domains in 
HIF-2α preventing its association with HIF-2β and sub-
sequent activation. PT2385 was the first such inhibitor of 
HIF-2α to enter clinical assessment. In a recently reported 
Phase I trial, 51 heavily pretreated patients with advanced 
clear cell RCC were enrolled to either the dose-escalation 
(26 patients) or expansion phase (25 patients) (36). PTC2385 
was well tolerated and ORR for the entire group was 14%. 
Clinical development continued with the closely related 
PT2977 (MK6482) which, following a Phase I dose-escala-
tion trial establishing the recommended Phase II dose, was 
recently assessed in an open-label Phase II trial in patients 
with advanced clear cell RCC with at least one prior treat-
ment (37, 38). Overall, 55 patients were enrolled and treated 
at a dose of 120 mg PO daily. The ORR was reported to be 
24% with a disease control rate, (Patients with stable dis-
ease + patients with partial responses + patients with com-
plete responses) of 80%, and median PFS was 11 months. 
The activity was observed across all IMDC risk groups. 
The results of a Phase II trial of MK6482 in patients with 
VHL syndrome and renal tumors were recently reported as 
well (39). Overall, 61 patients were enrolled in the study and 
treated with MK6482, also at 120 mg PO daily. At the time 
of the report, there were 27 (27.89%) confirmed responses 
and eight (13.1%) unconfirmed responses. The median dura-
tion of response and PFS had not yet been reached. Based 
on these results, MK6482 was granted breakthrough des-
ignation for patients with VHL disease-associated RCC in 
June 2020. MK6482 is currently being assessed in multiple 
Phase III trials as well as multiple combinations.
Another strategy to target HIF-2α is to reduce expres-
sion through RNA interference (RNAi). The development 
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of RNAi-based therapies has been challenged by delivery, 
poor bioavailability due to rapid degradation, poor cellu-
lar penetration, and preferential absorption by liver tissue. 
Arrowhead Therapeutics has developed a next-generation 
RNAi-based therapy directed against HIF-2α (ARO-HIF2) 
using a polyconjugate system designed to deliver to the tis-
sue outside the liver. ARO-HIF2 is currently being assessed 
in a Phase Ib trial in patients with advanced clear cell RCC 
(NCT04169711).
Glutamine antagonists
Similar to many other malignancies, clear cell RCC has 
been characterized by alternations in numerous metabolic 
pathways (40). In particular, clear cell RCC is believed to 
depend on the availability of glutamine due to a dependency 
on reductive carboxylation, a process in which glutamine is 
metabolized to form citrate for lipid biosynthesis (41). Glu-
tamine must be converted to glutamate in order to be uti-
lized by the cell. Many have proposed the hypothesis that the 
so-called “glutamine addiction” observed in clear cell RCC 
may be a therapeutic vulnerability that might be exploited 
through treatment with glutaminase inhibitors. Telaglenastat 
(CB-839) is a selective oral inhibitor of glutaminase which 
has shown preliminary activity in patients with RCC in com-
bination with both cabozantinib and everolimus. In the ini-
tial Phase I trial of the combination, 27 pretreated patients 
with both clear cell and papillary histology were enrolled and 
treated with the combination of CB-839 and everolimus. Of 
24 evaluable patients at the time of report, one patient expe-
rienced a PR while 21 had the best response of SD for an 
overall disease control rate of 92% (42). For the combination 
of CB-839 and cabozantinib, 13 heavily pretreated patients 
were enrolled and treated with the combination. Among 
12 evaluable patients, five patients experienced a PR (ORR 
42%) and seven had the best response of SD for a disease 
control rate of 100% (43). A randomized placebo-controlled 
Phase II trial (CANTATA) of CB-839 plus cabozantinib ver-
sus cabozantinib has been initiated and completed accrual 
although no results have yet been reported (NCT03428217). 
Based on the Phase I trial results, the combination of CB-839 
and cabozantinib was granted Fast Track designation by the 
FDA in May 2018. 
Adenosine 2A receptor inhibitor
Much effort has been directed towards enhancing the efficacy 
of immune checkpoint inhibitors in RCC. Preclinical studies 
have shown that adenosine accumulation in the tumor micro-
environment leads to the suppression of the immune activity of 
cytotoxic T-cell and natural killer (NK) cells and enhancement 
of the activity of regulatory T-cells (Tregs) and myeloid-de-
rived suppressor cells (MDSC) (44–46). Adenosine modulates 
the activity of immune cells by binding to adenosine 2A recep-
tor (A2AR) on the cell surface and has been implicated as a 
potential resistance mechanism to checkpoint inhibitors (47). 
Ciforadenant (CPI-444) is a small molecule that binds to 
A2AR and competitively inhibits its interaction with adenos-
ine. Ciforadenant was recently assessed in a Phase I trial alone 
and in combination with atezolizumab (PD-L1 Ab)  (48). 
Overall, 68 patients with pretreated advanced RCC were 
enrolled and treated with either ciforadenant monotherapy 
(33 patients) or the combination (35 patients). Most (72%) 
patients had previously been shown to be resistant or refrac-
tory to prior PD-1/PD-L1 Ab therapy. Four of 35 patients 
treated with the combination experienced PR (ORR 11%). 
Median PFS for the combination was 5.8 months. Appended 
correlative studies suggested that the efficacy of ciforadenant 
was associated with enhancement of immune function as 
noted by increased CD8+ T-cell infiltration and diversification 
of the TCR repertoire. The overall activity of the combina-
tion, in particular, was felt to be promising particularly in this 
heavily pretreated and largely checkpoint inhibitor-resistant/
refractory, PD-L1-low population. Ciforadenant is currently 
being developed broadly in other tumor types along with an 
adenosine gene signature biomarker (AdenoSig) developed as 
part of the original Phase I trial. 
Cytokines
The long-established efficacy of high dose (HD) interleukin 
2 (IL-2) in a subset of patients with advanced RCC has con-
tinued to stoke interest in the potential of cytokine therapy 
in this disease. Although HD IL-2 has been shown to reliably 
induce durable and complete remissions in a small group 
of patients with RCC, this therapy has been limited by its 
severe toxicity requiring inpatient delivery in specialized cen-
ters. Efforts continue to identify predictive models to limit 
its application to those most likely to benefit. In parallel, 
pharmaceutical companies have focused on developing novel 
agents that can both enhance the efficacy of IL-2 and reduce 
toxicity to allow outpatient administration. Bempegaldesleu-
kin (NKTR-214) is a pegylated CD122 preferential IL-2 ago-
nist designed to stimulate immune cells through the IL2βγ 
receptor with a limited engagement of the IL2αR subunit to 
stimulate CD8+ T and NK cells without the accompanying 
proliferation of Tregs observed with unmodified IL-2. After 
completing Phase I single-agent assessment, bempegaldesleu-
kin was recently studied in combination with nivolumab in 
patients with select solid tumors including RCC (49, 50). Of 
14 patients with previously untreated clear cell RCC treated 
with the combination in either the dose escalation or expan-
sion cohorts, 10 experienced a partial or complete response 
for an ORR of 71.4%. Based on these results, this combi-
nation is currently being assessed in a randomized Phase III 
trial compared with sunitinib or cabozatinib in patients with 
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Novel checkpoint inhibitors
Building upon the efficacy of the antibodies against PD-1 
and CTLA4, a bewildering array of other agents directed 
against other immune checkpoints have been developed and 
entered clinical assessment. These include agonistic anti-
bodies against co-stimulatory checkpoint pathways (e.g., 
CD27, OX40, ICOS, 4IBB) and blocking antibodies against 
co-inhibitory checkpoint pathways (e.g., LAG3, TIM3/
Galectin-9, TIGIT, GITR, Siglec15, VISTA, HLA-G/ILT4, 
BTLA). While none of these novel checkpoint inhibitors 
have entered dedicated RCC clinical trials, some preliminary 
activity in early phase clinical trials has been observed. For 
example, utomilumab, an agonistic antibody against 4IBB 
recently demonstrated promising activity in combination 
with pembrolizumab (58). Out of five patients treated with 
RCC, one patient experienced a CR while another experi-
enced a PR Translational studies have suggested that PD-1 
and LAG3 are the most frequently overexpressed check-
points in combination on circulating T-cells of patients with 
RCC (59). While a combination of BMS-986016 (LAG3 Ab) 
with nivolumab has shown promising activity in melanoma, 
similar results have not yet been disclosed in RCC (60). In 
general, the vast majority of these novel checkpoints are con-
tinuing in clinical development in combination with PD-1/
PD-L1 antibodies. Promising activity seen in early phase 
trials and dedicated expansion cohorts will hopefully soon 
inform Phase II and III trials in RCC. 
Future Perspective
The therapeutic bar in advanced clear cell RCC has been 
raised high in the first-line setting by the recent and expected 
approvals of multiple combinational regimens. In general, 
these regimens can reliably produce high response rates and 
prolonged responses. Nonetheless, complete responses that 
are durable off-therapy remain rare. Progress in developing 
new first-line regimens must therefore focus on enhancing 
the quality of response in terms of depth and durability 
rather than on incremental increases in response rate or PFS. 
Towards this end, a greater focus is expected on novel immu-
notherapies, particularly cytokines. With the vast majority 
of patients still requiring sequential therapies, there remain 
significant opportunities to assess novel agents. The novel 
inhibitors of HIF-2α present the most exciting opportunity 
to target the central molecular biology of RCC in rational 
combinations with other agents.
Conclusions
Significant improvements have been made in the therapy of 
patients with advanced clear cell RCC and recently approved 
combinational regimens have changed the standard of care in 
untreated advanced clear cell RCC (NCT03729245). Based 
on the results observed in patients with melanoma, bem-
pegaldesleukin was granted Breakthrough status by the FDA 
in August 2019 and its clinical development is moving for-
ward in numerous cancers including RCC. 
There are other versions of IL-2 in clinical development as 
well. ALKS 4230 is a recombinant formulation of IL-2 with 
intermediate affinity to IL2R, sparing interaction with and 
simulation of Tregs which are characterized by expression of 
high-affinity IL2R. ALKS 4230 is currently in clinical assess-
ment in a Phase I trial as a single agent and in combination 
with pembrolizumab (NCT02799095) (51). The trial is ongo-
ing and includes a cohort of patients with clear cell RCC. 
In addition to IL-2, there has been increased interest in 
other cytokines with similar biologic activity. IL-15 is an 
immunostimulatory cytokine whose receptor shares the same 
β and γ chains as the IL-2 receptor but contains a distinct α 
chain whose engagement results in stimulation of T cells and 
NK cells and maintenance of memory CD8+ T cells without 
expansion of T-regs (52). The development of unmodified 
IL-15 has been limited by toxicity and bioavailability and 
most strategies have focused on modified versions. AL-803 is 
a complex containing two IL-15 agonist domains associated 
with two IL-15α receptor domains fused to a human IgG1 
Fc which prolongs the half-life of the complex. AL-803 has 
recently been assessed in a Phase I trial including patients 
with advanced RCC in both subcutaneous and intravenous 
administrations (53). While no significant objective responses 
were observed, ALT-803 was associated with only mild cyto-
kine-related toxicities and there was evidence of expected 
T-cell and NK-cell expansion. ALT-803 then showed prom-
ising efficacy in a small Phase I trial in combination with 
nivolumab in patients with NSCLC (54). Further develop-
ment in other tumor types including RCC continues.
IL-12 is another proinflammatory cytokine that stimulates 
NK and T-cells to enhance proliferation and IFN-γ pro-
duction as well as to promote differentiation of T-cells into 
T helper 1 (Th1) cells (55). While the utilization of recom-
binant IL-12 as a therapy for advanced cancers has had a 
strong rationale, its application has been limited by toxicity, 
bioavailability, and a narrow therapeutic window induced by 
an apparent adaptive response to attenuate IL-12 effects (56). 
NHS-IL12 is an engineered immunocytokine in which two 
IL-12 heterodimers have been fused to the NSH76 antibody 
which targets regions of tumor necrosis to enhance on-tar-
get exposure and limit systemic toxicity. NHS-IL12 was 
recently assessed in a Phase I trial in patients with advanced 
malignancies (57). While no objective tumor responses were 
observed, pharmacodynamics studies showed evidence of 
increased T-cell receptor diversity and tumor-infiltrating 
lymphocytes (TIL) density. NHS-IL12 is currently being 
assessed in combination with avelumab in patients with solid 
tumors including patients with advanced RCC.
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the first-line setting. Ongoing Phase III trials will very likely 
add new combinational regimens to the standard options 
currently available. Despite this progress, the paucity of com-
plete and durable remissions resulting from treatment with 
current standard regimens highlights the need to continue to 
develop novel agents. As we have outlined, the development 
of novel inhibitors of HIF-2α and glutaminase continues to 
provide hope that agents targeting the fundamental biopsy 
of clear cell RCC will improve patient outcomes. In paral-
lel, a multitude of novel immunotherapies seeks to build on 
the established efficacy of cytokines and checkpoint inhib-
itors in this disease. While prolonged responses on sequen-
tial therapies are in clear progress, the goal remains to cure 
more patients with advanced clear cell RCC and achievement 
of this goal requires a commitment to novel therapeutic 
development.
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